PURPOSE: This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We enrolled subjects with bacillus Calmette-Guérin (BCG) refractory NMIBC to an early phase clinical trial of external deep pelvic hyperthermia (using a BSD-2000 device) combined with MMC. Bladders were heated to 42 °C for 1 h during intravesical MMC treatment. Treatments were given weekly for 6 weeks, then monthly for 4 months. Heating parameters, treatment toxicity, and clinical outcomes were systematically measured. RESULTS: Fifteen patients were enrolled on the clinical trial. Median age was 66 years and 87% were male. Median European Organisation for Research and Treatment of Cancer (EORTC) recurrence and progression scores were 6 and 8, respectively. The full treatment course was attained in 73% of subjects. Effective bladder heating was possible in all but one patient who could not tolerate the supine position due to lung disease. Adverse events were all minor (grade 2 or less) and no systemic toxicity was observed. The most common adverse effects were Foley catheter pain (40%), abdominal discomfort (33%), chemical cystitis symptoms (27%), and abdominal skin swelling (27%). With a median follow-up of 3.18 years, 67% experienced another bladder cancer recurrence (none were muscle invasive) and 13% experienced an upper tract recurrence. CONCLUSIONS: External deep pelvic hyperthermia using the BSD-2000 device is a safe and reproducible method of heating the bladder in patients undergoing intravesical MMC. The efficacy of this treatment modality should be explored further in clinical trials.
PURPOSE: This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We enrolled subjects with bacillus Calmette-Guérin (BCG) refractory NMIBC to an early phase clinical trial of external deep pelvic hyperthermia (using a BSD-2000 device) combined with MMC. Bladders were heated to 42 °C for 1 h during intravesical MMC treatment. Treatments were given weekly for 6 weeks, then monthly for 4 months. Heating parameters, treatment toxicity, and clinical outcomes were systematically measured. RESULTS: Fifteen patients were enrolled on the clinical trial. Median age was 66 years and 87% were male. Median European Organisation for Research and Treatment of Cancer (EORTC) recurrence and progression scores were 6 and 8, respectively. The full treatment course was attained in 73% of subjects. Effective bladder heating was possible in all but one patient who could not tolerate the supine position due to lung disease. Adverse events were all minor (grade 2 or less) and no systemic toxicity was observed. The most common adverse effects were Foley catheter pain (40%), abdominal discomfort (33%), chemical cystitis symptoms (27%), and abdominal skin swelling (27%). With a median follow-up of 3.18 years, 67% experienced another bladder cancer recurrence (none were muscle invasive) and 13% experienced an upper tract recurrence. CONCLUSIONS: External deep pelvic hyperthermia using the BSD-2000 device is a safe and reproducible method of heating the bladder in patients undergoing intravesical MMC. The efficacy of this treatment modality should be explored further in clinical trials.
Authors: J L Au; R A Badalament; M G Wientjes; D C Young; J A Warner; P L Venema; D L Pollifrone; J D Harbrecht; J L Chin; S P Lerner; B J Miles Journal: J Natl Cancer Inst Date: 2001-04-18 Impact factor: 13.506
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Michael R Abern; Richmond A Owusu; Mark R Anderson; Edward N Rampersaud; Brant A Inman Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908
Authors: A G van der Heijden; L A Kiemeney; O N Gofrit; O Nativ; A Sidi; Z Leib; R Colombo; R Naspro; M Pavone; J Baniel; F Hasner; J A Witjes Journal: Eur Urol Date: 2004-07 Impact factor: 20.096
Authors: O N Gofrit; A Shapiro; D Pode; A Sidi; O Nativ; Z Leib; J A Witjes; A G van der Heijden; R Naspro; R Colombo Journal: Urology Date: 2004-03 Impact factor: 2.649
Authors: H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee Journal: Int J Hyperthermia Date: 2020 Impact factor: 3.914
Authors: Thomas A Longo; Ajay Gopalakrishna; Matvey Tsivian; Megan Van Noord; Coen R Rasch; Brant A Inman; Elisabeth D Geijsen Journal: Int J Hyperthermia Date: 2016-05-01 Impact factor: 3.914
Authors: Roger Li; Debasish Sundi; Jingsong Zhang; Youngchul Kim; Richard J Sylvester; Philippe E Spiess; Michael A Poch; Wade J Sexton; Peter C Black; James M McKiernan; Gary D Steinberg; Ashish M Kamat; Scott M Gilbert Journal: Eur Urol Date: 2020-03-04 Impact factor: 20.096
Authors: Titania Juang; Paul R Stauffer; Oana A Craciunescu; Paolo F Maccarini; Yu Yuan; Shiva K Das; Mark W Dewhirst; Brant A Inman; Zeljko Vujaskovic Journal: Int J Hyperthermia Date: 2014-03-26 Impact factor: 3.914
Authors: Dan-Dan Xu; Men Ding; Pan Tong; Yan-Yun Chong; Wei-Yu Gu; Yang Li; Xin-Jiang Fang; Ning Li Journal: Oncol Rep Date: 2020-07-07 Impact factor: 3.906